125 related articles for article (PubMed ID: 20041946)
1. What changes in health-related quality of life matter to multiple myeloma patients? A prospective study.
Kvam AK; Fayers P; Wisloff F
Eur J Haematol; 2010 Apr; 84(4):345-53. PubMed ID: 20041946
[TBL] [Abstract][Full Text] [Related]
2. Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma.
Kvam AK; Fayers PM; Wisloff F
Eur J Haematol; 2011 Oct; 87(4):330-7. PubMed ID: 21668504
[TBL] [Abstract][Full Text] [Related]
3. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
Musoro JZ; Coens C; Greimel E; King MT; Sprangers MAG; Nordin A; van Dorst EBL; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
Gynecol Oncol; 2020 Nov; 159(2):515-521. PubMed ID: 32972782
[TBL] [Abstract][Full Text] [Related]
4. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
5. Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma.
Kvam AK; Wisløff F; Fayers PM
Health Qual Life Outcomes; 2010 Aug; 8():79. PubMed ID: 20678240
[TBL] [Abstract][Full Text] [Related]
6. Minimal important differences in the EORTC QLQ-C30 in patients with advanced cancer.
Bedard G; Zeng L; Zhang L; Lauzon N; Holden L; Tsao M; Danjoux C; Barnes E; Sahgal A; Poon M; Chow E
Asia Pac J Clin Oncol; 2014 Jun; 10(2):109-17. PubMed ID: 23551530
[TBL] [Abstract][Full Text] [Related]
7. Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma.
Musoro JZ; Bottomley A; Coens C; Eggermont AM; King MT; Cocks K; Sprangers MA; Groenvold M; Velikova G; Flechtner HH; Brandberg Y;
Eur J Cancer; 2018 Nov; 104():169-181. PubMed ID: 30359910
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
Delforge M; Dhawan R; Robinson D; Meunier J; Regnault A; Esseltine DL; Cakana A; van de Velde H; Richardson PG; San Miguel JF
Eur J Haematol; 2012 Jul; 89(1):16-27. PubMed ID: 22469559
[TBL] [Abstract][Full Text] [Related]
9. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma.
Cocks K; Cohen D; Wisløff F; Sezer O; Lee S; Hippe E; Gimsing P; Turesson I; Hajek R; Smith A; Graham L; Phillips A; Stead M; Velikova G; Brown J;
Eur J Cancer; 2007 Jul; 43(11):1670-8. PubMed ID: 17574838
[TBL] [Abstract][Full Text] [Related]
10. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.
Verelst SG; Termorshuizen F; Uyl-de Groot CA; Schaafsma MR; Ammerlaan AH; Wittebol S; Sinnige HA; Zweegman S; van Marwijk Kooy M; van der Griend R; Lokhorst HM; Sonneveld P; Wijermans PW;
Ann Hematol; 2011 Dec; 90(12):1427-39. PubMed ID: 21472373
[TBL] [Abstract][Full Text] [Related]
11. Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy.
Musoro JZ; Sodergren SC; Coens C; Pochesci A; Terada M; King MT; Sprangers MAG; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
Colorectal Dis; 2020 Dec; 22(12):2278-2287. PubMed ID: 32767619
[TBL] [Abstract][Full Text] [Related]
12. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences.
Gulbrandsen N; Hjermstad MJ; Wisløff F;
Eur J Haematol; 2004 Mar; 72(3):172-80. PubMed ID: 14962235
[TBL] [Abstract][Full Text] [Related]
13. Symptoms and quality of life in chronic pancreatitis assessed by structured interview and the EORTC QLQ-C30 and QLQ-PAN26.
Fitzsimmons D; Kahl S; Butturini G; van Wyk M; Bornman P; Bassi C; Malfertheiner P; George SL; Johnson CD
Am J Gastroenterol; 2005 Apr; 100(4):918-26. PubMed ID: 15784041
[TBL] [Abstract][Full Text] [Related]
14. Is it useful to calculate sum scores of the quality of life questionnaire EORTC QLQ-C30?
Hinz A; Einenkel J; Briest S; Stolzenburg JU; Papsdorf K; Singer S
Eur J Cancer Care (Engl); 2012 Sep; 21(5):677-83. PubMed ID: 22624663
[TBL] [Abstract][Full Text] [Related]
15. Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types.
Musoro JZ; Coens C; Sprangers MAG; Brandberg Y; Groenvold M; Flechtner HH; Cocks K; Velikova G; Dirven L; Greimel E; Singer S; Pogoda K; Gamper EM; Sodergren SC; Eggermont A; Koller M; Reijneveld JC; Taphoorn MJB; King MT; Bottomley A;
Eur J Cancer; 2023 Jul; 188():171-182. PubMed ID: 37257278
[TBL] [Abstract][Full Text] [Related]
16. The European Organization for Research and Treatment of Cancer QLQ-C30: an examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30.
Guzelant A; Goksel T; Ozkok S; Tasbakan S; Aysan T; Bottomley A
Eur J Cancer Care (Engl); 2004 May; 13(2):135-44. PubMed ID: 15115469
[TBL] [Abstract][Full Text] [Related]
17. Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients.
Dirven L; Musoro JZ; Coens C; Reijneveld JC; Taphoorn MJB; Boele FW; Groenvold M; van den Bent MJ; Stupp R; Velikova G; Cocks K; Sprangers MAG; King MT; Flechtner HH; Bottomley A
Neuro Oncol; 2021 Aug; 23(8):1327-1336. PubMed ID: 33598685
[TBL] [Abstract][Full Text] [Related]
18. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.
Dubois D; Dhawan R; van de Velde H; Esseltine D; Gupta S; Viala M; de la Loge C
J Clin Oncol; 2006 Feb; 24(6):976-82. PubMed ID: 16432077
[TBL] [Abstract][Full Text] [Related]
19. Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial.
Kawahara T; Taira N; Shiroiwa T; Hagiwara Y; Fukuda T; Uemura Y; Mukai H
Qual Life Res; 2022 Jun; 31(6):1829-1836. PubMed ID: 34982354
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry.
Mols F; Oerlemans S; Vos AH; Koster A; Verelst S; Sonneveld P; van de Poll-Franse LV
Eur J Haematol; 2012 Oct; 89(4):311-9. PubMed ID: 22762785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
